Practical Considerations for Monitoring Patients With Chronic Myeloid Leukemia

Seminars in Hematology

Volumn 47, Issue 4, 2010, Pages 327-334

  Branford, Susan ^a   Hughes, Timothy P ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; DASATINIB; IMATINIB; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; OCTAMER TRANSCRIPTION FACTOR 1;

ARTICLE; CANCER DIAGNOSIS; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MONITORING; GENETIC VARIABILITY; HUMAN; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RNA ANALYSIS; SEQUENCE ANALYSIS; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS; CYTOGENETIC ANALYSIS; DRUG MONITORING; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PIPERAZINES; PYRIMIDINES;

EID: 77957026184     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2010.06.007     Document Type: Article

References (57)

1. Lahaye T., Riehm B., Berger U., et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer 2005, 103:1659-1669.
2. Landstrom A.P., Tefferi A. Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia. Leuk Lymphoma 2006, 47:397-402.
3. Testoni N., Marzocchi G., Luatti S., et al. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood 2009, 114:4939-4943.
4. Baccarani M., Cortes J., Pane F., et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009, 27:6041-6051.
5. Demehri S., Paschka P., Schultheis B., et al. e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants?. Leukemia 2005, 19:681-684.
6. Hughes T., Deininger M., Hochhaus A., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
7. Branford S., Fletcher L., Cross N.C.P., et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008, 112:3330-3338.
8. Muller M.C., Cross N.C.P., Erben P., et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009, 23:1957-1963.
9. Cross N.C.P. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009, 22:355-365.
10. Ross D.M., Branford S., Melo J.V., Hughes T.P. Reply to 'What do we mean by sensitivity when we talk about detecting minimal residual disease?'. by Steinbach and Debatin. Leukemia 2008, 23:819-820.
11. Armbruster D.A., Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008, 29:S49-S52.
12. Bose S., Deininger M., Gora-Tybor J., Goldman J.M., Melo J.V. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998, 92:3362-3367.
13. Branford S., Hughes T.P., Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics. Br J Haematol. 1999, 107:587-599.
14. Rousselot P., Huguet F., Rea D., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007, 109:58-60.
15. Gabert J., Beillard E., van der Velden V.H., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 2003, 17:2318-2357.
16. Branford S., Seymour J.F., Grigg A., et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res. 2007, 13:7080-7085.
17. Marin D., Khorashad J.S., Foroni L., et al. Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?. Br J Haematol. 2009, 145:373-375.
18. Press R.D., Galderisi C., Yang R., et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res. 2007, 13:6136-6143.
19. Kantarjian H., O'Brien S., Shan J., et al. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?. Cancer 2008, 112:837-845.
20. Apperley J.F. Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007, 8:1018-1029.
21. Branford S., Melo J.V., Hughes T.P. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?. Blood 2009, 114:5426-5435.
22. Branford S., Rudzki Z., Parkinson I., et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004, 104:2926-2932.
23. Wang L., Knight K., Lucas C., Clark R.E. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica 2006, 91:235-239.
24. Press R.D., Willis S.G., Laudadio J., Mauro M.J., Deininger M.W.N. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood 2009, 114:2598-2605.
25. Branford S., Rudzki Z., Walsh S., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102:276-283.
26. Hughes T., Saglio G., Branford S., et al. Impact of baseline BCR-ABL mmutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009, 27:4204-4210.
27. Muller M.C., Cortes J.E., Kim D.-W., et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 2009, 114:4944-4953.
28. Shah N.P., Skaggs B.J., Branford S., et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007, 117:2562-2569.
29. Soverini S., Gnani A., Colarossi S., et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009, 114:2168-2171.
30. Redaelli S., Piazza R., Rostagno R., et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol. 2009, 27:469-471.
31. Gruber F.X., Ernst T., Kiselev Y., Hochhaus A., Mikkola I. Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment. Clin Chem. 2009, clinchem.2009.133843.
32. Willis S.G., Lange T., Demehri S., et al. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005, 106:2128-2137.
33. Stratton M.R., Campbell P.J., Futreal P.A. The cancer genome. Nature 2009, 458:719-724.
34. Roche-Lestienne C., Soenen-Cornu V., Grardel-Duflos N., et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002, 100:1014-1018.
35. Radich J.P. The biology of CML blast crisis. Hematology 2007, 2007:384-391.
36. Crossman L.C., O'Hare T., Lange T., et al. A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib. Leukemia 2005, 19:1859-1862.
37. Ernst T., Hoffmann J., Erben P., et al. ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica 2008, 93:1389-1393.
38. Gruber F.X., Hjorth-Hansen H., Mikkola I., Stenke L., Johansen T. A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib. Leukemia 2006, 20:2057-2060.
39. Sherbenou D.W., Hantschel O., Turaga L., et al. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia. Leukemia 2008, 22:1184-1190.
40. Branford S., Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Myeloid leukemia: methods and protocols, methods in molecular medicine 2006, Vol. 125:93-106. Humana Press, Totawa, NJ. H. Illand, M. Hertzgerg, P. Marlton (Eds.).
41. Laudadio J., Deininger M.W.N., Mauro M.J., Druker B.J., Press R.D. An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. J Mol Diagn. 2008, 10:177-180.
42. Quigley N.B., Henley D.C., Hubbard R.A. ABL kinase domain pseudoexon insertion is not uncommon in BCR-ABL transcripts. J Mol Diagn. 2008, 10:475-476.
43. Lee T.-S., Ma W., Zhang X., et al. BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Mol Cancer Ther. 2008, 7:3834-3841.
44. Peng B., Hayes M., Resta D., et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004, 22:935-942.
45. Picard S., Titier K., Etienne G., et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496-3499.
46. Larson R.A., Druker B.J., Guilhot F., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008, 111:4022-4028.
47. Forrest D.L., Trainor S., Brinkman R.R., et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res. 2009, 33:271-275.
48. Mahon F.-X. Pharmacologic monitoring and determinants of intracytoplasmic drug levels. Best Pract Res Clin Haematol. 2009, 22:381-386.
49. White D.L., Saunders V.A., Dang P., et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007, 110:4064-4072.
50. Wang L., Giannoudis A., Lane S., Williamson P., Pirmohamed M., Clark R.E. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther. 2008, 83:258-264.
51. White D., Saunders V., Grigg A., et al. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J Clin Oncol. 2007, 25:4445-4451.
52. Dulucq S., Bouchet S., Turcq B., et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008, 112:2024-2027.
53. Oehler V.G., Yeung K.Y., Choi Y.E., Bumgarner R.E., Raftery A.E., Radich J.P. The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data. Blood 2009, 114:3292-3298.
54. Zhang W.W., Cortes J.E., Yao H., et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol. 2009, 27:3642-3649.
55. McWeeney S.K., Pemberton L.C., Loriaux M.M., et al. A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood 2010, 115:315-325.
56. Yong A.S.M., Szydlo R.M., Goldman J.M., Apperley J.F., Melo J.V. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 2006, 107:205-212.
57. Zheng C., Li L., Haak M., et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 2006, 20:1028-1034.